CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 76 enrolled
Drug / intervention
ReCell® Autologous Cell Harvesting Devicedevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03333941
NCT03333941N/ACompleted

Continued Access Protocol: A Prospective, Multicenter, Single-Arm, Observational Study of the Safety and Clinical Performance of RES (Regenerative Epithelial Suspension) Prepared With the ReCell® Device Combined With Meshed Skin Graft in the Treatment of Acute Burn Injuries

Avita Medical·observational·Posted Nov 7, 2017·Updated Jul 30, 2024

In Brief

An observational study evaluating ReCell® Autologous Cell Harvesting Device for Burns. Completed, enrolled 76 participants across 6 sites.

Detailed Summary

The overall purpose of this continued access study is to allow ongoing treatment of subjects at selected investigational sites while the marketing application for the ReCell® Autologous Cell Harvesting Device is under FDA review. This is a prospective, multicenter, single-arm observational study to evaluate the safety and clinical performance of the ReCell® device when used as an adjunct to meshed autografts in patients with acute thermal burn injuries requiring skin grafting for closure.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsBurns
CountriesUnited States

Timeline

N/ACompletedFinished
201820192020202120222023202420252026
First PostedNov 7, 2017
Enrollment StartOct 26, 2017
Primary CompletionDec 19, 2018
Study CompletionMay 8, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.7 years ago

Interventions

ReCell® Autologous Cell Harvesting Devicedevice

RES (Regenerative Epithelial Suspension) derived from the use of the ReCell® device will be applied over skin grafts meshed more widely than conventional autografting.